Cited by 143Heart Failure Treatment and ManagementHeart rate and cardiovascular healthCardiovascular Function and Risk Factors

Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF

Deedwania, Prakash C., Giles, Thomas D., Klibaner, Michael, Ghali, Jalal K., Herlitz, Johan, Hildebrandt, Per, Kjekshus, John, Spinar, Jindrich +3 more·2005·American Heart Journal

Abstract

Background The objective of the current study was to examine the efficacy and tolerability of the beta-blocker metoprolol succinate controlled release/extended release (CR/XL) in patients with diabetes in the Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF).Methods The Cox proportional hazards model was used to calculate hazard ratios (HR) for convenience expressed as relative risks (risk reduction = 1-HR), and 95% confidence intervals (CI).Results The risk of hospitalization for heart failure was 76% higher in diabetics compared to non-diabetics (95% CI 38% to 123%). Metoprolol CR/XL was well tolerated and reduced the risk of hospitalization for heart failure by 37% in the diabetic group (95% CI 53% to 15%), and by 35% in the non-diabetic group (95% CI 48% to 19%). Pooling of mortality data from the Cardiac Insufficiency Bisoprolol Study II (CIBIS II), MERIT-HF, and the Carvedilol Prospective Randomized Cumulative Survival Study (COPERNICUS) showed similar survival benefits in patients with diabetes (25%; 95% CI 40% to 4%) and without diabetes (36%; 95% CI 44% to 27%); test of diabetes by treatment interaction was non-significant. Adverse events were reported more often on placebo than on metoprolol CR/XL.Conclusions Patients with heart failure and diabetes have a much higher risk of hospitalization than patients without diabetes. Regardless of diabetic status, a highly significant reduction in hospitalizations for heart failure was observed with metoprolol CR/XL therapy, which was very well tolerated also by patients with diabetes. Furthermore, the pooled data showed a statistically significant survival benefit in patients with diabetes.

Integrity signals

Registry

Crossref · 10.1016/j.ahj.2004.05.056

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Deedwania, P. C., Giles, T. D., Klibaner, M., Ghali, J. K., Herlitz, J., Hildebrandt, P., Kjekshus, J., Spinar, J., Vitovec, J., Stanbrook, H., & Wikstrand, J.
Affiliations
  • Veterans Health Administration (US)
  • Louisiana State University (US)
  • AstraZeneca (United States) (US)
  • Sahlgrenska University Hospital (SE)
  • Oslo University Hospital (NO)
Corresponding author
Deedwania, Prakash C.
Venue
American Heart Journal
Publisher
Elsevier BV
Published
2005-01
Volume
149
Issue
1
Pages
159-167
ISSN
0002-8703 (ISSN-L)
OpenAlex
W1980524591
Cited by
143
References
21
Citations by year
2026: 2 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 7 · 2020: 8 · 2019: 10 · 2018: 6 · 2017: 7 · 2016: 10 · 2015: 7 · 2014: 11 · 2013: 2 · 2012: 2
FWCI
9.34
Type
journal article
Language
en
Open access
closed
Locations
  • American Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Borås Academic Digital Archive (University of Borås) (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
metoprolol succinate, beta-blockers, chronic heart failure, diabetes mellitus, heart failure hospitalization, survival benefit, drug tolerability, adverse events, Copernicus
MeSH terms
Adrenergic beta-Antagonists, Adult, Aged, Delayed-Action Preparations, Diabetes Mellitus, Double-Blind Method, Female, Heart Failure, Hospitalization, Humans, Male, Metoprolol, Middle Aged, Risk, Proportional Hazards Models, Survival Analysis, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review